High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice

Identifying the impact of a patient's ethnicity on treatment responses in clinical practice may assist in providing individualized treatment regimens for chronic hepatitis C (CHC). The effectiveness of standard peginterferon plus ribavirin therapy and the need for triple combination therapy wit...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and molecular hepatology 2013, 19(1), , pp.60-69
Main Authors: Heo, Nae-Yun, Lim, Young-Suk, Lee, Han Chu, Lee, Yung Sang, Kim, Kang Mo, Byun, Kwan Soo, Han, Kwang-Hyub, Lee, Kwan Sik, Paik, Seung Woon, Yoon, Seung Kew, Suh, Dong Jin
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Antiviral Agents - therapeutic use
Antiviral drugs
Asian Continental Ancestry Group
Asian people
Clinical medicine
Clinical trials
Cohort Studies
Combination therapy
Drug dosages
Drug Therapy, Combination
Female
Genotype
Genotype & phenotype
Hepacivirus - genetics
Hepatitis C
Hepatitis C, Chronic - drug therapy
Humans
Interferon-alpha - therapeutic use
Liver cancer
Liver cirrhosis
Liver diseases
Male
Medication adherence
Middle Aged
Odds Ratio
Original
Patients
Peginterferon alfa-2a
Polyethylene Glycols - therapeutic use
Predictive Value of Tests
Recombinant Proteins - therapeutic use
Republic of Korea
Ribavirin
Ribavirin - therapeutic use
Ribonucleic acid
RNA
RNA, Viral - genetics
Treatment Outcome
Young Adult
내과학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Identifying the impact of a patient's ethnicity on treatment responses in clinical practice may assist in providing individualized treatment regimens for chronic hepatitis C (CHC). The effectiveness of standard peginterferon plus ribavirin therapy and the need for triple combination therapy with protease inhibitors in Koreans remain matters of debate. These issues were investigated in the present study. The clinical data of 272 treatment-naïve Korean CHC patients who were treated in a community-based clinical trial (Clinical Trial group; n=51) and in clinical practice (Cohort group; n=221), were analyzed and compared. All were treated with standard protocols of peginterferon alfa-2a plus ribavirin therapy. For patients with hepatitis C virus (HCV) genotype 1, the sustained virological response (SVR) rates in the Clinical Trial and Cohort groups were 81% (21/26) and 55% (58/106), respectively, by intention-to-treat (ITT) analysis (P=0.02), and 100% (13/13) and 80% (32/40), respectively, in treatment-adherent patients (P=0.18). For patients with HCV genotype 2, the SVR rates in these two groups were 96% (24/25) and 88% (101/115), respectively, by ITT analysis (P=0.31). Adherence and treatment duration were independent predictors of SVR for genotypes 1 and 2, respectively (P
ISSN:2287-2728
2287-285X
DOI:10.3350/cmh.2013.19.1.60